Analysis of vesicular monoamine transporter 2 polymorphisms in Parkinson's disease

Neurobiology of Aging

Volumn 34, Issue 6, 2013, Pages 1712.e9-1712.e13

  Brighina, Laura ^a   Riva, Chiara ^b   Bertola, Francesca ^b   Saracchi, Enrico ^a,b   Fermi, Silvia ^b   Goldwurm, Stefano ^c   Ferrarese, Carlo ^a,b  

^a SAN GERARDO HOSPITAL   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c PARKINSON INSTITUTE   (Italy)

Author keywords

Association; Parkinson's disease; SNP; Vesicular monoamine transporter 2

Indexed keywords

GENOMIC DNA; VESICULAR MONOAMINE TRANSPORTER 2;

5' UNTRANSLATED REGION; ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE LOCATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC MODEL; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; PARKINSON DISEASE; PRIORITY JOURNAL; PROMOTER REGION; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; VMAT2 GENE;

EID: 84875278440     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2012.12.020     Document Type: Article

References (24)

1. Attia J., Ioannidis J.P., Thakkinstian A., McEvoy M., Scott R.J., Minelli C., Thompson J., Infante-Rivard C., Guyatt G. How to use an article about genetic association: B: are the results of the study valid?. JAMA 2009, 301:191-197.
2. Barrett J.C., Fry B., Maller J., Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21:263-265.
3. Bohnen N.I., Albin R.L., Koeppe R.A., Wernette K.A., Kilbourn M.R., Minoshima S., Frey K.A. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J. Cereb. Blood Flow Metab. 2006, 26:1198-1212.
4. Caudle W.M., Richardson J.R., Wang M.Z., Taylor T.N., Guillot T.S., McCormack A.L., Colebrooke R.E., Di Monte D.A., Emson P.C., Miller G.W. Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J. Neurosci. 2007, 27:8138-8148.
5. Chen M.K., Kuwabara H., Zhou Y., Adams R.J., Brasić J.R., McGlothan J.L., Verina T., Burton N.C., Alexander M., Kumar A., Wong D.F., Guilarte T.R. VMAT2 and dopamine neuron loss in a primate model of Parkinson's disease. J. Neurochem. 2008, 105:78-90.
6. Christiansen L., Tan Q., Iachina M., Bathum L., Kruse T.A., McGue M., Christensen K. Candidate gene polymorphisms in the serotonergic pathway: influence on depression symptomatology in an elderly population. Biol. Psychiatry 2007, 61:223-230.
7. Crowley J.J., Lipsky R.H., Lucki I., Berrettini W.H. Variation in the genes encoding vesicular monoamine transporter 2 and beta-1 adrenergic receptor and antidepressant treatment outcome. Psychiatr. Genet. 2008, 18:248-251.
8. Gelb D.J., Oliver E., Gilman S. Diagnostic criteria for Parkinson disease. Arch. Neurol. 1999, 56:33-39.
9. Glatt C.E., DeYoung J.A., Delgado S., Service S.K., Giacomini K.M., Edwards R.H., Risch N., Freimer N.B. Screening a large reference sample to identify very low frequency sequence variants: comparisons between two genes. Nat. Genet. 2001, 27:435-438.
10. Glatt C.E., Wahner A.D., White D.J., Ruiz-Linares A., Ritz B. Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women. Hum. Mol. Genet. 2006, 15:299-305.
11. Kageyama R., Pastan I. Molecular cloning and characterization of a human DNA binding factor that represses transcription. Cell 1989, 59:815-825.
12. Kariya S., Hirano M., Takahashi N., Furiya Y., Ueno S. Lack of association between polymorphic microsatellites of the VMAT2 gene and Parkinson's disease in Japan. J. Neurol. Sci. 2005, 232:91-94.
13. Lee C.S., Samii A., Sossi V., Ruth T.J., Schulzer M., Holden J.E., Wudel J., Pal P.K., de la Fuente-Fernandez R., Calne D.B., Stoessl A.J. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann. Neurol. 2000, 47:493-503.
14. Lin Z., Walther D., Yu X.Y., Li S., Drgon T., Uhl G.R. SLC18A2 promoter haplotypes and identification of a novel protective factor against alcoholism. Hum. Mol. Genet. 2005, 14:1393-1404.
15. Martin W.R., Wieler M., Stoessl A.J., Schulzer M. Dihydrotetrabenazine positron emission tomography imaging in early, untreated Parkinson's disease. Ann. Neurol. 2008, 63:388-394.
16. Mizuta I., Satake W., Nakabayashi Y., Ito C., Suzuki S., Momose Y., Nagai Y., Oka A., Inoko H., Fukae J., Saito Y., Sawabe M., Murayama S., Yamamoto M., Hattori N., Murata M., Toda T. Multiple candidate gene analysis identifies alpha-synuclein as a susceptibility gene for sporadic Parkinson's disease. Hum. Mol. Genet. 2006, 15:1151-1158.
17. Mooslehner K.A., Chan P.M., Xu W., Liu L., Smadja C., Humby T., Allen N.D., Wilkinson L.S., Emson P.C. Mice with very low expression of the vesicular monoamine transporter 2 gene survive into adulthood: potential mouse model for parkinsonism. Mol. Cell. Biol. 2001, 21:5321-5331.
18. Okamura N., Villemagne V.L., Drago J., Pejoska S., Dhamija R.K., Mulligan R.S., Ellis J.R., Ackermann U., O'Keefe G., Jones G., Kung H.F., Pontecorvo M.J., Skovronsky D., Rowe C.C. In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133. J. Nucl. Med. 2010, 51:223-228.
19. Peter D., Liu Y., Sternini C., de Giorgio R., Brecha N., Edwards R.H. Differential expression of two vesicular monoamine transporters. J. Neurosci. 1995, 15:6179-6188.
20. Sala G., Brighina L., Saracchi E., Fermi S., Riva C., Carrozza V., Pirovano M., Ferrarese C. Vesicular monoamine transporter 2 mRNA levels are reduced in platelets from patients with Parkinson's disease. J. Neural. Transm. 2010, 117:1093-1098.
21. Schaid D.J., Rowland C.M., Tines D.E., Jacobson R.M., Poland G.A. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am. J. Hum. Genet. 2002, 70:425-434.
22. Schwab S.G., Franke P.E., Hoefgen B., Guttenthaler V., Lichtermann D., Trixler M., Knapp M., Maier W., Wildenauer D.B. Association of DNA polymorphisms in the synaptic vesicular amine transporter gene (SLC18A2) with alcohol and nicotine dependence. Neuropsychopharmacology 2005, 30:2263-2268.
23. Spina M.B., Cohen G. Dopamine turnover and glutathione oxidation: implications for Parkinson disease. Proc. Natl. Acad. Sci. U. S. A. 1989, 86:1398-1400.
24. Taylor T.N., Caudle W.M., Miller G.W. VMAT2-Deficient mice display nigral and extranigral pathology and motor and nonmotor symptoms of Parkinson's disease. Parkinsons Dis. 2011, 2011:124-165.